Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Pancreatic Cancer | Correction

Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox

Authors: Shogo Amano, Seiji Kaino, Shuhei Shinoda, Hirofumi Harima, Toshihiko Matsumoto, Koichi Fujisawa, Taro Takami, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida

Published in: BMC Cancer | Issue 1/2023

Login to get access

Excerpt

Correction: BMC Cancer 20, 681 (2020) …
Literature
1.
Metadata
Title
Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
Authors
Shogo Amano
Seiji Kaino
Shuhei Shinoda
Hirofumi Harima
Toshihiko Matsumoto
Koichi Fujisawa
Taro Takami
Naoki Yamamoto
Takahiro Yamasaki
Isao Sakaida
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11091-y

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis

Research

Predictive power of PEN-3 cultural model in cervical cancer screening among women: a cross- sectional study in South of Iran

Research

Implementation of a home-based colorectal cancer screening intervention in Malaysia (CRC-SIM)

Research

GDNF-RET signaling and EGR1 form a positive feedback loop that promotes tamoxifen resistance via cyclin D1

Study Protocol

Vaginal CO2 laser therapy for genitourinary syndrome in breast cancer survivors—VagLaser study protocol: a randomized blinded, placebo-controlled trial

Research

Association of meat consumption with the risk of gastrointestinal cancers: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits